­xxxxxxxxxxx

Policy and Public Affairs Advisor

Lymphoma Action

3 Cromwell Court

New Street

Aylesbury

Bucks HP20 2PB

Sent by e-mail only: xxxxxxxxxxxxxxxxxxxxxxxxxx

19 October 2022

Dear xxxx

**Final Appraisal Document — Tafasitamab with Lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]**

I acknowledge receipt of your email dated 27 September 2022 confirming that you are happy to proceed with the response in my initial scrutiny letter. We will use your appeal letter and the initial scrutiny letter for the appeal.

Yours sincerely

Dr Mark Chakravarty

Lead Non-executive Director for Appeals

National Institute for Health and Care Excellence